Eric Joseph
Stock Analyst at JP Morgan
(1.96)
# 1,293
Out of 4,611 analysts
115
Total ratings
39.19%
Success rate
-9.86%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IGMS IGM Biosciences | Downgrades: Underweight | $12 → $9 | $15.41 | -41.60% | 5 | Oct 1, 2024 | |
| WVE Wave Life Sciences | Reinstates: Overweight | $10 → $13 | $8.41 | +54.58% | 1 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $23 → $21 | $6.53 | +221.59% | 5 | Sep 10, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | n/a | $0.57 | - | 2 | Aug 15, 2024 | |
| NVAX Novavax | Maintains: Underweight | $8 → $9 | $13.61 | -33.87% | 7 | Aug 12, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $55 → $54 | $47.32 | +14.12% | 4 | Aug 8, 2024 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $45 → $48 | $23.41 | +105.04% | 3 | Aug 7, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Underweight | $11 → $10 | $11.41 | -12.36% | 4 | Aug 6, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $50 → $54 | $16.41 | +229.07% | 2 | Aug 6, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $34 | $22.20 | +53.15% | 6 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.77 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 | $35.10 | +51.00% | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $3.51 | +327.35% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $12 | $7.74 | +55.04% | 4 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $10.48 | +43.13% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $22.23 | +12.46% | 3 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $47 | $43.06 | +9.15% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $5.38 | +11.52% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $6.11 | +63.67% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $5.09 | +116.11% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $28.24 | +45.18% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $5 | $1.22 | +309.84% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $1.55 | +222.58% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $48 | $11.53 | +316.31% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.46 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $8.27 | +33.01% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.30 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $0.89 | +801.51% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $8.16 | +3,576.47% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.77 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $5.00 | +900.00% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $11 | $1.03 | +971.92% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $3.98 | +126.13% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.33 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $3.75 | +1,020.00% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $4.30 | +202.33% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.78 | +1,308.45% | 3 | Nov 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.49 | - | 3 | Mar 2, 2018 |
IGM Biosciences
Oct 1, 2024
Downgrades: Underweight
Price Target: $12 → $9
Current: $15.41
Upside: -41.60%
Wave Life Sciences
Sep 27, 2024
Reinstates: Overweight
Price Target: $10 → $13
Current: $8.41
Upside: +54.58%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $6.53
Upside: +221.59%
bluebird bio
Aug 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.57
Upside: -
Novavax
Aug 12, 2024
Maintains: Underweight
Price Target: $8 → $9
Current: $13.61
Upside: -33.87%
Revolution Medicines
Aug 8, 2024
Maintains: Overweight
Price Target: $55 → $54
Current: $47.32
Upside: +14.12%
Beam Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $23.41
Upside: +105.04%
Enanta Pharmaceuticals
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $11.41
Upside: -12.36%
Rocket Pharmaceuticals
Aug 6, 2024
Maintains: Overweight
Price Target: $50 → $54
Current: $16.41
Upside: +229.07%
Nurix Therapeutics
Jul 15, 2024
Maintains: Overweight
Price Target: $31 → $34
Current: $22.20
Upside: +53.15%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.77
Upside: -
Jun 20, 2024
Maintains: Overweight
Price Target: $53
Current: $35.10
Upside: +51.00%
May 13, 2024
Maintains: Overweight
Price Target: $16 → $15
Current: $3.51
Upside: +327.35%
May 3, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $7.74
Upside: +55.04%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $10.48
Upside: +43.13%
Apr 18, 2024
Reiterates: Overweight
Price Target: $25
Current: $22.23
Upside: +12.46%
Feb 23, 2024
Maintains: Overweight
Price Target: $34 → $47
Current: $43.06
Upside: +9.15%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $5.38
Upside: +11.52%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $6.11
Upside: +63.67%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $5.09
Upside: +116.11%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $28.24
Upside: +45.18%
Aug 28, 2023
Downgrades: Neutral
Price Target: $15 → $5
Current: $1.22
Upside: +309.84%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $1.55
Upside: +222.58%
Aug 10, 2023
Maintains: Overweight
Price Target: $47 → $48
Current: $11.53
Upside: +316.31%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.46
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.27
Upside: +33.01%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $11.30
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $8
Current: $0.89
Upside: +801.51%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $8.16
Upside: +3,576.47%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.77
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $5.00
Upside: +900.00%
Apr 26, 2021
Initiates: Underweight
Price Target: $11
Current: $1.03
Upside: +971.92%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $3.98
Upside: +126.13%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.33
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $3.75
Upside: +1,020.00%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $4.30
Upside: +202.33%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.78
Upside: +1,308.45%
Mar 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $1.49
Upside: -